Herbal bioactivation, molecular targets and the toxicity relevance

Chemico-Biological Interactions

Volumn 192, Issue 3, 2011, Pages 161-176

  Chen, Xiao Wu ^a   Serag, Erini S ^b   Sneed, Kevin B ^b   Zhou, Shu Feng ^c  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cytochrome P450; Herbal medicine; Metabolic activation; Target; Toxicity

Indexed keywords

ALPRAZOLAM; ARISTOLOCHIC ACID; CAPSAICIN; COUMARIN; DISOBULBIN D; DITERPENOID; ESTRAGOLE; HERBACEOUS AGENT; KAVA; KAVALACTONE; METHYLEUGENOL; OLEUROPEIN; PLANT MEDICINAL PRODUCT; PULEGONE; QUERCETIN; RESVERATROL; SAFROLE; TERPENOID; TEUCHAMAEDRYN A; TEUCRIN A; UNCLASSIFIED DRUG;

CARCINOGENESIS; CARCINOGENICITY; DNA ADDUCT; DRUG ACTIVATION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG POTENTIATION; FUNCTIONAL PROTEOMICS; GENE ACTIVATION; GENE MUTATION; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; LIVER CIRRHOSIS; LIVER NECROSIS; LIVER TOXICITY; METABOLOMICS; NONHUMAN; ONCOGENE H RAS; ONCOGENE MYC; SHORT SURVEY; SIDE EFFECT; SKIN DISEASE; TOXIC HEPATITIS; UROGENITAL TRACT CANCER;

ALLIUM SATIVUM; ARISTOLOCHIA; CAPSICUM FRUTESCENS; PIPER METHYSTICUM; TEUCRIUM; VITACEAE;

EID: 79957630531     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2011.03.016     Document Type: Review

References (139)

1. S.F. Zhou, E. Chan, L.Y. Lim, U.A. Boelsterli, S.C. Li, J.C. Wang, Q. Zhang, M. Huang, A.L. Xu, Drugs behave as mechanism-based inhibitors of cytochrome P450 3A4, Curr. Drug Metab. 5 (2004) 415-442.
2. S. Zhou, E. Chan, L.Y. Lim, U.A. Boelsterli, S.C. Li, J. Wang, Q. Zhang, M. Huang, A. Xu, Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4, Curr. Drug Metab. 5 (2004) 415-442.
3. S. Zhou, E. Chan, W. Duan, M. Huang, Y.Z. Chen, Drug bioactivation, covalent binding to target proteins and toxicity relevance, Drug Metab. Rev. 37 (2005) 41-213. (Pubitemid 40259715)
4. A.P. Li, Overview: evaluation of metabolism-based drug toxicity in drug development, Chem. Biol. Interact. 179 (2009) 1-3.
5. S.F. Zhou, C.C. Xue, X.Q. Yu, G. Wang, Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update, Curr. Drug Metab. 8 (2007) 526-553.
6. B.M. Dietz, J.L. Bolton, Biological reactive intermediates (BRIs) formed from botanical dietary supplements, Chem. Biol. Interact. (2011) [Epub ahead of print], doi:10.1016/j.cbi.2010.10.007.
7. L. Zhao, G. Pickering, Paracetamol metabolism and related genetic differences, Drug Metab. Rev. 43 (2011) 41-52.
8. J.A. Hinson, D.W. Roberts, L.P. James, Mechanisms of acetaminophen- induced liver necrosis, Handb. Exp. Pharmacol. (2010) 369-405.
9. E. Ernst, Systematic reviews of herbal medicines, Am. J. Med. 117 (2004) 533. author reply 533.
10. D.H. Mehta, P.M. Gardiner, R.S. Phillips, E.P. McCarthy, Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions, J. Altern. Complement. Med. 14 (2008) 1263-1269.
11. S. Gunther, R.E. Patterson, A.R. Kristal, K.L. Stratton, E. White, Demographic and health-related correlates of herbal and specialty supplement use, J. Am. Diet. Assoc. 104 (2004) 27-34. (Pubitemid 38058295)
12. E. Ernst, Herbal medicines: balancing benefits and risks, Novartis Found. Symp. 282 (2007) 154-167. discussion 167-172, 212-158.
13. S.A. Jordan, D.G. Cunningham, R.J. Marles, Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment, Toxicol. Appl. Pharmacol. 243 (2010) 198-216.
14. R.T. Tovar, R.M. Petzel, Herbal toxicity, Dis. Mon. 55 (2009) 592-641.
15. R.T. Tovar, Clinical approach to clinical herbal toxicity, Semin. Diagn. Pathol. 26 (2009) 28-37.
16. E. Ernst, Toxic heavy metals and undeclared drugs in Asian herbal medicines, Trends Pharmacol. Sci. 23 (2002) 136-139.
17. Z. Hu, X. Yang, P.C. Ho, S.Y. Chan, P.W. Heng, E. Chan, W. Duan, H.L. Koh, S. Zhou, Herb-drug interactions: a literature review, Drugs 65 (2005) 1239-1282. (Pubitemid 41038418)
18. X.X. Yang, Z.P. Hu, W. Duan, Y.Z. Zhu, S.F. Zhou, Drug-herb interactions: eliminating toxicity with hard drug design, Curr. Pharm. Des. 12 (2006) 4649-4664. (Pubitemid 44835152)
19. A. Fugh-Berman, Herb-drug interactions, Lancet 355 (2000) 134-138. (Pubitemid 30068565)
20. Y.M. Di, C.G. Li, C.C. Xue, S.F. Zhou, Clinical drugs that interact with St. John's wort and implication in drug development, Curr. Pharm. Des. 14 (2008) 1723-1742. (Pubitemid 351998596)
21. D.A. Kennedy, D. Seely, Clinically based evidence of drug-herb interactions: a systematic review, Expert Opin. Drug Saf. 9 (2010) 79-124.
22. S.M. He, C.G. Li, J.P. Liu, E. Chan, W. Duan, S.F. Zhou, Disposition pathways and pharmacokinetics of herbal medicines in humans, Curr. Med. Chem. 17 (2010) 4072-4113.
23. S.F. Zhou, Z.W. Zhou, M. Huang, Pharmacokinetics and disposition of plant natural products in humans and the clinical and toxicological implications, Curr. Org. Chem. 14 (2010) 1732-1756.
24. J.I. Pitt, Chinese herbal medicines, aristolochic acid and Balkan endemic nephropathy, Occup. Environ. Med. 68 (2011) 237.
25. F.D. Debelle, J.L. Vanherweghem, J.L. Nortier, Aristolochic acid nephropathy: a worldwide problem, Kidney Int. 74 (2008) 158-169. (Pubitemid 351915079)
26. H. de Jonge, Y. Vanrenterghem, Aristolochic acid: the common culprit of Chinese herbs nephropathy and Balkan endemic nephropathy, Nephrol. Dial. Transplant. 23 (2008) 39-41. (Pubitemid 351767414)
27. J.L. Vanherweghem, M. Depierreux, C. Tielemans, D. Abramowicz, M. Dratwa, M. Jadoul, C. Richard, D. Vandervelde, D. Verbeelen, R. Vanhaelen-Fastre, et al., Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs, Lancet 341 (1993) 387-391. (Pubitemid 23048140)
28. G. Bamias, J. Boletis, Balkan nephropathy: evolution of our knowledge, Am. J. Kidney Dis. 52 (2008) 606-616.
29. M.N. Lai, S.M. Wang, P.C. Chen, Y.Y. Chen, J.D. Wang, Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk, J. Natl Cancer Inst. 102 (2010) 179-186.
30. M. Stiborova, E. Frei, V.M. Arlt, H.H. Schmeiser, Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy, Mutat. Res. 658 (2008) 55-67. (Pubitemid 351172880)
31. S. Shibutani, R.R. Bonala, T. Rosenquist, R. Rieger, N. Suzuki, F. Johnson, F. Miller, A.P. Grollman, Detoxification of aristolochic acid I by Odemethylation: less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents, Int. J. Cancer 127 (2010) 1021-1027.
32. T.A. Rosenquist, H.J. Einolf, K.G. Dickman, L. Wang, A. Smith, A.P. Grollman, Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse, Drug Metab. Dispos. 38 (2010) 761-768.
33. Y. Xiao, M. Ge, X. Xue, C. Wang, H. Wang, X. Wu, L. Li, L. Liu, X. Qi, Y. Zhang, Y. Li, H. Luo, T. Xie, J. Gu, J. Ren, Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity, Kidney Int. 73 (2008) 1231-1239. (Pubitemid 351693146)
34. Y. Xiao, X. Xue, Y.F. Wu, G.Z. Xin, Y. Qian, T.P. Xie, L.K. Gong, J. Ren, B-Naphthoflavone protects mice from aristolochic acid-I-induced acute kidney injury in a CYP1A dependent mechanism, Acta Pharmacol. Sin. 30 (2009) 1559-1565.
35. H.H. Schmeiser, M. Stiborova, V.M. Arlt, Chemical and molecular basis of the carcinogenicity of Aristolochia plants, Curr Opin Drug Discov Devel 12 (2009) 141-148.
36. G.M. Lord, M. Hollstein, V.M. Arlt, C. Roufosse, C.D. Pusey, T. Cook, H.H. Schmeiser, DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy, Am. J. Kidney Dis. 43 (2004) e11-e17.
37. A.P. Grollman, S. Shibutani, M. Moriya, F. Miller, L. Wu, U. Moll, N. Suzuki, A. Fernandes, T. Rosenquist, Z. Medverec, K. Jakovina, B. Brdar, N. Slade, R.J. Turesky, A.K. Goodenough, R. Rieger, M. Vukelic, B. Jelakovic, Aristolochic acid and the etiology of endemic (Balkan) nephropathy, Proc. Natl Acad. Sci. USA 104 (2007) 12129-12134. (Pubitemid 47185641)
38. N. Slade, U.M. Moll, B. Brdar, A. Zoric, B. Jelakovic, P53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy, Mutat. Res. 663 (2009) 1-6.
39. S. Shibutani, H. Dong, N. Suzuki, S. Ueda, F. Miller, A.P. Grollman, Selective toxicity of aristolochic acids I and II, Drug Metab. Dispos. 35 (2007) 1217-1222.
40. L. Zhou, P. Fu, X.R. Huang, F. Liu, A.C. Chung, K.N. Lai, H.Y. Lan, Mechanism of chronic aristolochic acid nephropathy: role of Smad3, Am J Physiol Renal Physiol 298 (2010) F1006-F1017.
41. L. Zhou, P. Fu, X.R. Huang, F. Liu, K.N. Lai, H.Y. Lan, Activation of p53 promotes renal injury in acute aristolochic acid nephropathy, J. Am. Soc. Nephrol. 21 (2010) 31-41.
42. H.Z. Wu, L. Guo, Y.F. Mak, N. Liu, W.T. Poon, Y.W. Chan, Z. Cai, Proteomics investigation on aristolochic acid nephropathy: a case study on rat kidney tissues, Anal. Bioanal. Chem. 399 (2011) 3431-3439.
43. V.M. Arlt, J. Zuo, K. Trenz, C.A. Roufosse, G.M. Lord, J.L. Nortier, H.H. Schmeiser, M. Hollstein, D.H. Phillips, Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice, Int. J. Cancer 128 (2011) 21-32.
44. K.B. Salah, M.A. Mahjoub, J.P. Chaumont, L. Michel, J. Millet-Clerc, I. Chraeif, S. Ammar, Z. Mighri, M. Aouni, Chemical composition and in vitro antifungal and antioxidant activity of the essential oil and methanolic extract of Teucrium sauvagei Le Houerou, Nat. Prod. Res. 20 (2006) 1089-1097. (Pubitemid 44824421)
45. M. Ma, Z. Jiang, J. Ruan, X. Tan, J. Liu, C. Wang, X.M. Zha, L. Zhang, The furano norclerodane diterpenoid disobulbin-D induces apoptosis in normal human liver L-02 cells, Exp. Toxicol. Pathol. (2011) [Epub ahead of print].
46. J.Z. Zhang, Zeng Sheng Ping tables-induced hepatic damage, Adverse Drug React. J. 3 (2007) 24.
47. A. Druckova, L.J. Marnett, Characterization of the amino acid adducts of the enedial derivative of teucrin A, Chem. Res. Toxicol. 19 (2006) 1330-1340. (Pubitemid 44607319)
48. M. Lekehal, D. Pessayre, J.M. Lereau, C. Moulis, I. Fouraste, D. Fau, Hepatotoxicity of the herbal medicine germander: metabolic activation of its furano diterpenoids by cytochrome P450 3A Depletes cytoskeleton-associated protein thiols and forms plasma membrane blebs in rat hepatocytes, Hepatology 24 (1996) 212-218. (Pubitemid 26249436)
49. V. De Berardinis, C. Moulis, M. Maurice, P. Beaune, D. Pessayre, D. Pompon, J. Loeper, Human microsomal epoxide hydrolase is the target of germander-induced autoantibodies on the surface of human hepatocytes, Mol. Pharmacol. 58 (2000) 542-551.
50. M. Widersten, A. Gurell, D. Lindberg, Structure-function relationships of epoxide hydrolases and their potential use in biocatalysis, Biochim. Biophys. Acta 1800 (2010) 316-326.
51. J. Loeper, V. De Berardinis, C. Moulis, P. Beaune, D. Pessayre, D. Pompon, Human epoxide hydrolase is the target of germander autoantibodies on the surface of human hepatocytes: enzymatic implications, Adv. Exp. Med. Biol. 500 (2001) 121-124. (Pubitemid 34106985)
52. D. Polymeros, D. Kamberoglou, V. Tzias, Acute cholestatic hepatitis caused by Teucrium polium (golden germander) with transient appearance of antimitochondrial antibody, J. Clin. Gastroenterol. 34 (2002) 100-101.
53. R.L. Smith, T.B. Adams, J. Doull, V.J. Feron, J.I. Goodman, L.J. Marnett, P.S. Portoghese, W.J. Waddell, B.M. Wagner, A.E. Rogers, J. Caldwell, I.G. Sipes, Safety assessment of allylalkoxybenzene derivatives used as flavouring substances - methyl eugenol and estragole, Food Chem. Toxicol. 40 (2002) 851-870.
54. I.M. Rietjens, M.G. Boersma, H. van der Woude, S.M. Jeurissen, M.E. Schutte, G.M. Alink, Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk, Mutat. Res. 574 (2005) 124-138.
55. S.M. Jeurissen, A. Punt, M.G. Boersma, J.J. Bogaards, Y.C. Fiamegos, B. Schilter, P.J. van Bladeren, N.H. Cnubben, I.M. Rietjens, Human cytochrome P450 enzyme specificity for the bioactivation of estragole and related alkenylbenzenes, Chem. Res. Toxicol. 20 (2007) 798-806. (Pubitemid 46953687)
56. T.M. Guenthner, G. Luo, Investigation of the role of the 2′,3′-epoxidation pathway in the bioactivation and genotoxicity of dietary allylbenzene analogs, Toxicology 160 (2001) 47-58. (Pubitemid 32200463)
57. G. Luo, T.M. Guenthner, Covalent binding to DNA in vitro of 2′,3′-oxides derived from allylbenzene analogs, Drug Metab. Dispos. 24 (1996) 1020-1027.
58. L.V. Iyer, M.N. Ho, W.M. Shinn, W.W. Bradford, M.J. Tanga, S.S. Nath, C.E. Green, Glucuronidation of 1′-hydroxyestragole (1′-HE) by human UDP-glucuronosyltransferases UGT2B7 and UGT1A9, Toxicol. Sci. 73 (2003) 36-43.
59. S.M. Jeurissen, J.J. Bogaards, H.M. Awad, M.G. Boersma, W. Brand, Y.C. Fiamegos, T.A. van Beek, G.M. Alink, E.J. Sudholter, N.H. Cnubben, I.M. Rietjens, Human cytochrome P450 enzyme specificity for bioactivation of safrole to the proximate carcinogen 1′-hydroxysafrole, Chem. Res. Toxicol. 17 (2004) 1245-1250. (Pubitemid 39265880)
60. Y.F. Ueng, C.H. Hsieh, M.J. Don, C.W. Chi, L.K. Ho, Identification of the main human cytochrome P450 enzymes involved in safrole 1′-hydroxylation, Chem. Res. Toxicol. 17 (2004) 1151-1156.
61. J.L. Bolton, N.M. Acay, V. Vukomanovic, Evidence that 4-allyl-o-quinones spontaneously rearrange to their more electrophilic quinone methides: potential bioactivation mechanism for the hepatocarcinogen safrole, Chem. Res. Toxicol. 7 (1994) 443-450. (Pubitemid 24150107)
62. W. Meinl, C. Donath, H. Schneider, Y. Sommer, H. Glatt, SULT1C3, an orphan sequence of the human genome, encodes an enzyme activating various promutagens, Food Chem. Toxicol. 46 (2008) 1249-1256. (Pubitemid 351258199)
63. T.Y. Liu, Y.T. Chung, P.F. Wang, C.W. Chi, L.L. Hsieh, Safrole-DNA adducts in human peripheral blood - an association with areca quid chewing and CYP2E1 polymorphisms, Mutat. Res. 559 (2004) 59-66.
64. J.M. Lee, T.Y. Liu, D.C. Wu, H.C. Tang, J. Leh, M.T. Wu, H.H. Hsu, P.M. Huang, J.S. Chen, C.J. Lee, Y.C. Lee, Safrole-DNA adducts in tissues from esophageal cancer patients: clues to areca-related esophageal carcinogenesis, Mutat. Res. 565 (2005) 121-128.
65. Y.T. Chung, C.L. Chen, C.C. Wu, S.A. Chan, C.W. Chi, T.Y. Liu, Safrole-DNA adduct in hepatocellular carcinoma associated with betel quid chewing, Toxicol. Lett. 183 (2008) 21-27.
66. J. Beyer, D. Ehlers, H.H. Maurer, Abuse of nutmeg (Myristica fragrans Houtt.): studies on the metabolism and the toxicologic detection of its ingredients elemicin, myristicin, and safrole in rat and human urine using gas chromatography/mass spectrometry, Ther. Drug Monit. 28 (2006) 568-575. (Pubitemid 44181492)
67. S.M. Jeurissen, J.J. Bogaards, M.G. Boersma, J.P. ter Horst, H.M. Awad, Y.C. Fiamegos, T.A. van Beek, G.M. Alink, E.J. Sudholter, N.H. Cnubben, I.M. Rietjens, Human cytochrome P450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1′-hydroxymethyleugenol, Chem. Res. Toxicol. 19 (2006) 111-116.
68. I. Gardner, H. Wakazono, P. Bergin, I. de Waziers, P. Beaune, J.G. Kenna, J. Caldwell, Cytochrome P450 mediated bioactivation of methyleugenol to 1′-hydroxymethyleugenol in Fischer 344 rat and human liver microsomes, Carcinogenesis 18 (1997) 1775-1783.
69. M.E. Riveiro, N. De Kimpe, A. Moglioni, R. Vazquez, F. Monczor, C. Shayo, C. Davio, Coumarins: old compounds with novel promising therapeutic perspectives, Curr. Med. Chem. 17 (2010) 1325-1338.
70. L. Wu, X. Wang, W. Xu, F. Farzaneh, R. Xu, The structure and pharmacological functions of coumarins and their derivatives, Curr. Med. Chem. 16 (2009) 4236-4260.
71. K. Abraham, F. Wohrlin, O. Lindtner, G. Heinemeyer, A. Lampen, Toxicology and risk assessment of coumarin: focus on human data, Mol. Nutr. Food Res. 54 (2010) 228-239.
72. A. Lacy, R. O'Kennedy, Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer, Curr. Pharm. Des. 10 (2004) 3797-3811. (Pubitemid 39409871)
73. S.P. Felter, J.D. Vassallo, B.D. Carlton, G.P. Daston, A safety assessment of coumarin taking into account species-specificity of toxicokinetics, Food Chem. Toxicol. 44 (2006) 462-475.
74. B.G. Lake, Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment, Food Chem. Toxicol. 37 (1999) 423-453. (Pubitemid 29335767)
75. J.D. Vassallo, S.M. Hicks, G.P. Daston, L.D. Lehman-McKeeman, Metabolic detoxification determines species differences in coumarin-induced hepatotoxicity, Toxicol. Sci. 80 (2004) 249-257.
76. X. Zhuo, J. Gu, Q.Y. Zhang, D.C. Spink, L.S. Kaminsky, X. Ding, Biotransformation of coumarin by rodent and human cytochromes P450: metabolic basis of tissue-selective toxicity in olfactory mucosa of rats and mice, J. Pharmacol. Exp. Ther. 288 (1999) 463-471. (Pubitemid 29119652)
77. S.L. Born, D. Caudill, K.L. Fliter, M.P. Purdon, Identification of the cytochromes P450 that catalyze coumarin 3, 4-epoxidation and 3-hydroxylation, Drug Metab. Dispos. 30 (2002) 483-487. (Pubitemid 34456966)
78. B. Nair, Final report on the safety assessment of Mentha piperita (peppermint) oil, Mentha piperita (peppermint) leaf extract, Mentha piperita (peppermint) leaf, and Mentha piperita (peppermint) leaf water, Int. J. Toxicol. 20 (Suppl. 3) (2001) 61-73.
79. A. Andersen, Final report on the safety assessment of sodium p-chloro-m-cresol, p-chloro-m-cresol, chlorothymol, mixed cresols, m-cresol, o-cresol, p-cresol, isopropyl cresols, thymol, o-cymen-5-ol, and carvacrol, Int. J. Toxicol. 25 (Suppl. 1) (2006) 29-127.
80. D. Thomassen, N. Knebel, J.T. Slattery, R.H. McClanahan, S.D. Nelson, Reactive intermediates in the oxidation of menthofuran by cytochromes P-450, Chem. Res. Toxicol. 5 (1992) 123-130.
81. L.J. Chen, E.H. Lebetkin, L.T. Burka, Metabolism of (R)-(+)-menthofuran in Fischer-344 rats: identification of sulfonic acid metabolites, Drug Metab. Dispos. 31 (2003) 1208-1213.
82. L.J. Chen, E.H. Lebetkin, L.T. Burka, Metabolism of (R)-(+)-pulegone in F344 rats, Drug Metab. Dispos. 29 (2001) 1567-1577.
83. C. Chen, J. Zhou, C. Ji, Quercetin: a potential drug to reverse multidrug resistance, Life Sci. 87 (2010) 333-338.
84. M. Harwood, B. Danielewska-Nikiel, J.F. Borzelleca, G.W. Flamm, G.M. Williams, T.C. Lines, A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties, Food Chem. Toxicol. 45 (2007) 2179-2205. (Pubitemid 47451573)
85. H.M. Awad, M.G. Boersma, S. Boeren, P.J. Van Bladeren, J. Vervoort, I.M. Rietjens, Quenching of quercetin quinone/quinone methides by different thiolate scavengers: stability and reversibility of conjugate formation, Chem. Res. Toxicol. 16 (2003) 822-831. (Pubitemid 36898996)
86. H.M. Awad, M.G. Boersma, S. Boeren, P.J. vanBladeren, J. Vervoort, I.M. Rietjens, Structure-activity study on the quinone/quinone methide chemistry of flavonoids, Chem. Res. Toxicol. 14 (2001) 398-408.
87. H.M. Awad, M.G. Boersma, S. Boeren, P.J. van Bladeren, J. Vervoort, I.M. Rietjens, The regioselectivity of glutathione adduct formation with flavonoid quinone/quinone methides is pH-dependent, Chem. Res. Toxicol. 15 (2002) 343-351. (Pubitemid 34241372)
88. L. Reyes-Escogido Mde, E.G. Gonzalez-Mondragon, E. Vazquez-Tzompantzi, Chemical and pharmacological aspects of capsaicin, Molecules 16 (2011) 1253-1270.
89. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin, Int. J. Toxicol. 26 (Suppl. 1) (2007) 3-106.
90. C.A. Reilly, W.J. Ehlhardt, D.A. Jackson, P. Kulanthaivel, A.E. Mutlib, R.J. Espina, D.E. Moody, D.J. Crouch, G.S. Yost, Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells, Chem. Res. Toxicol. 16 (2003) 336-349.
91. C.A. Reilly, G.S. Yost, Metabolism of capsaicinoids by P450 enzymes: a review of recent findings on reaction mechanisms, bio-activation, and detoxification processes, Drug Metab. Rev. 38 (2006) 685-706. (Pubitemid 44903263)
92. C.A. Reilly, G.S. Yost, Structural and enzymatic parameters that determine alkyl dehydrogenation/hydroxylation of capsaicinoids by cytochrome P450 enzymes, Drug Metab. Dispos. 33 (2005) 530-536.
93. M. Gannett, P. Iversen, T. Lawson, The mechanism of inhibition of cytochrome P450IIE1 by dihydrocapsaicin, Bioorg. Chem. 18 (1990) 185-198.
94. S. Oikawa, E. Nagao, K. Sakano, S. Kawanishi, Mechanism of oxidative DNA damage induced by capsaicin, a principal ingredient of hot chili pepper, Free Radic. Res. 40 (2006) 966-973. (Pubitemid 44480560)
95. Y.J. Surh, S.S. Lee, Capsaicin, a double-edged sword: toxicity, metabolism, and chemopreventive potential, Life Sci. 56 (1995) 1845-1855.
96. G. Aviello, L. Abenavoli, F. Borrelli, R. Capasso, A.A. Izzo, F. Lembo, B. Romano, F. Capasso, Garlic: empiricism or science?, Nat Prod. Commun. 4 (2009) 1785-1796.
97. B.C. Foster, M.S. Foster, S. Vandenhoek, A. Krantis, J.W. Budzinski, J.T. Arnason, K.D. Gallicano, S. Choudri, An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic, J. Pharm. Pharm. Sci. 4 (2001) 176-184.
98. K. Fujita, T. Kamataki, Screening of organosulfur compounds as inhibitors of human CYP2A6, Drug Metab. Dispos. 29 (2001) 983-989.
99. R. Kishimoto, M. Ueda, H. Yoshinaga, K. Goda, S.S. Park, Combined effects of ethanol and garlic on hepatic ethanol metabolism in mice, J. Nutr. Sci. Vitaminol. 45 (1999) 275-286. (Pubitemid 29330338)
100. B.J. Gurley, S.F. Gardner, M.A. Hubbard, D.K. Williams, W.B. Gentry, Y. Cui, C.Y. Ang, Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans, Clin. Pharmacol. Ther. 72 (2002) 276-287.
101. M.E. Fitzsimmons, J.M. Collins, Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P450 3A4: potential contribution to high first-pass metabolism, Drug Metab. Dispos. 25 (1997) 256-266.
102. R.J. Krause, S.C. Glocke, A.A. Elfarra, Sulfoxides as urinary metabolites of S-allyl-L-cysteine in rats: evidence for the involvement of flavin-containing monooxygenases, Drug Metab. Dispos. 30 (2002) 1137-1142.
103. J.F. Brady, H. Ishizaki, J.M. Fukuto, M.C. Lin, A. Fadel, J.M. Gapac, C.S. Yang, Inhibition of cytochrome P-450 2E1 by diallyl sulfide and its metabolites, Chem. Res. Toxicol. 4 (1991) 642-647.
104. M.C. Lin, E.J. Wang, C. Patten, M.J. Lee, F. Xiao, K.R. Reuhl, C.S. Yang, Protective effect of diallyl sulfone against acetaminophen-induced hepatotoxicity in mice, J. Biochem. Toxicol. 11 (1996) 11-20.
105. P.D. Premdas, R.J. Bowers, P.G. Forkert, Inactivation of hepatic CYP2E1 by an epoxide of diallyl sulfone, J. Pharmacol. Exp. Ther. 293 (2000) 1112-1120. (Pubitemid 30417883)
106. J. Sarris, E. LaPorte, I. Schweitzer, Kava: a comprehensive review of efficacy, safety, and psychopharmacology, Aust. NZ J. Psychiatry 45 (2011) 27-35.
107. P.A. Whitton, A. Lau, A. Salisbury, J. Whitehouse, C.S. Evans, Kava lactones and the kava-kava controversy, Phytochemistry 64 (2003) 673-679. (Pubitemid 37176400)
108. B.M. Johnson, S.X. Qiu, S. Zhang, F. Zhang, J.E. Burdette, L. Yu, J.L. Bolton, R.B. van Breemen, Identification of novel electrophilic metabolites of piper methysticum Forst (Kava), Chem. Res. Toxicol. 16 (2003) 733-740.
109. J.M. Mathews, A.S. Etheridge, S.R. Black, Inhibition of human cytochrome P450 activities by kava extract and kavalactones, Drug Metab. Dispos. 30 (2002) 1153-1157.
110. J.M. Mathews, A.S. Etheridge, J.L. Valentine, S.R. Black, D.P. Coleman, P. Patel, J. So, L.T. Burka, Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro, Drug Metab. Dispos. 33 (2005) 1555-1563.
111. M. Unger, U. Holzgrabe, W. Jacobsen, C. Cummins, L.Z. Benet, Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava), Planta Med. 68 (2002) 1055-1058.
112. Y. Ma, K. Sachdeva, J. Liu, M. Ford, D. Yang, I.A. Khan, C.O. Chichester, B. Yan, Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23, Drug Metab. Dispos. 32 (2004) 1317-1324.
113. J.L. Raucy, Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products, Drug Metab. Dispos. 31 (2003) 533-539.
114. J.C. Almeida, E.W. Grimsley, Coma from the health food store: interaction between Kava and alprazolam, Ann. Intern. Med. 125 (1996) 940-941.
115. J.C. Gorski, D.R. Jones, M.A. Hamman, S.A. Wrighton, S.D. Hall, Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily, Xenobiotica 29 (1999) 931-944. (Pubitemid 29454386)
116. L. Zou, M.R. Harkey, G.L. Henderson, Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity, Life Sci. 71 (2002) 1579-1589. (Pubitemid 34808718)
117. J.H. Shon, J.Y. Park, M.S. Kim, I.J. Cha, B.H. Chun, J.G. Shin, Effect of licorice (Radix glycyrrhizae) on the pharmacokinetics and pharmacodynamics of midazolam in healthy subjects (abstract), Clin. Pharmacol. Ther. 69 (2001) P78.
118. A. Misra, N. Singhal, L. Khurana, Obesity, the metabolic syndrome, and type 2 diabetes in developing countries: role of dietary fats and oils, J. Am. Coll. Nutr. 29 (2010) 289S-301S.
119. M. Servili, S. Esposto, R. Fabiani, S. Urbani, A. Taticchi, F. Mariucci, R. Selvaggini, G.F. Montedoro, Phenolic compounds in olive oil: antioxidant, health and organoleptic activities according to their chemical structure, Inflammopharmacology 17 (2009) 76-84.
120. I. Stupans, M. Murray, A. Kirlich, K.L. Tuck, P.J. Hayball, Inactivation of cytochrome P450 by the food-derived complex phenol oleuropein, Food Chem. Toxicol. 39 (2001) 1119-1124.
121. I. Stupans, G. Stretch, P. Hayball, Olive oil phenols inhibit human hepatic microsomal activity, J. Nutr. 130 (2000) 2367-2370.
122. A. Tsarbopoulos, E. Gikas, N. Papadopoulos, N. Aligiannis, A. Kafatos, Simultaneous determination of oleuropein and its metabolites in plasma by high-performance liquid chromatography, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 785 (2003) 157-164. (Pubitemid 36078446)
123. K.L. Tuck, P.J. Hayball, Major phenolic compounds in olive oil: metabolism and health effects, J. Nutr. Biochem. 13 (2002) 636-644.
124. E. Miro-Casas, M.I. Covas, M. Farre, M. Fito, J. Ortuno, T. Weinbrenner, P. Roset, R. De La Torre, Hydroxytyrosol disposition in humans, Clin. Chem. 49 (2003) 945-952.
125. S. D'Angelo, C. Manna, V. Migliardi, O. Mazzoni, P. Morrica, G. Capasso, G. Pontoni, P. Galletti, V. Zappia, Pharmacokinetics and metabolism of hydroxytyrosol, a natural antioxidant from olive oil, Drug Metab. Dispos. 29 (2001) 1492-1498. (Pubitemid 33000698)
126. T. Szekeres, M. Fritzer-Szekeres, P. Saiko, W. Jager, Resveratrol and resveratrol analogues - structure-activity relationship, Pharm. Res. 27 (2010) 1042-1048.
127. Resveratrol, Monograph, Altern. Med. Rev. 15 (2010) 152-158.
128. P.A. Kroon, A. Iyer, P. Chunduri, V. Chan, L. Brown, The cardiovascular nutrapharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential, Curr Med Chem 17 (2010) 2442-2455.
129. K.R. Patel, E. Scott, V.A. Brown, A.J. Gescher, W.P. Steward, K. Brown, Clinical trials of resveratrol, Ann. NY Acad. Sci. 1215 (2011) 161-169.
130. J.A. Crowell, P.J. Korytko, R.L. Morrissey, T.D. Booth, B.S. Levine, Toxicol. Sci. 82 (2004) 614-619.
131. C.H. Cottart, V. Nivet-Antoine, C. Laguillier-Morizot, J.L. Beaudeux, Resveratrol bioavailability and toxicity in humans, Mol. Nutr. Food Res. 54 (2010) 7-16.
132. D. Delmas, A. Lancon, D. Colin, B. Jannin, N. Latruffe, Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer, Curr. Drug Targets 7 (2006) 423-442. (Pubitemid 43744833)
133. B. Piver, M. Fer, X. Vitrac, J.M. Merillon, Y. Dreano, F. Berthou, D. Lucas, Involvement of cytochrome P450 1A2 in the biotransformation of transresveratrol in human liver microsomes, Biochem. Pharmacol. 68 (2004) 773-782.
134. W.K. Chan, A.B. Delucchi, Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4, Life Sci. 67 (2000) 3103-3112.
135. W.K. Chan, L.T. Nguyen, V.P. Miller, R.Z. Harris, Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine, Life Sci. 62 (1998) 135-142.
136. B. Piver, F. Berthou, Y. Dreano, D. Lucas, Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components, Toxicol. Lett. 125 (2001) 83-91. (Pubitemid 33043758)
137. R. Mikstacka, D. Przybylska, A.M. Rimando, W. Baer-Dubowska, Inhibition of human recombinant cytochromes P450 CYP1A1 and CYP1B1 by transresveratrol methyl ethers, Mol. Nutr. Food Res. 51 (2007) 517-524. (Pubitemid 47083688)
138. B. Piver, F. Berthou, Y. Dreano, D. Lucas, Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages, Life Sci. 73 (2003) 1199-1213.
139. B. Wen, W.L. Fitch, Analytical strategies for the screening and evaluation of chemically reactive drug metabolites, Expert. Opin. Drug Metab. Toxicol. 5 (2009) 39-55.